Day: January 25, 2024

FORT WORTH, Texas, Jan. 25, 2024 (GLOBE NEWSWIRE) — American Airlines Group Inc. (NASDAQ: AAL) today reported its fourth-quarter and full-year 2023 financial results, including:Record full-year revenue of approximately $53 billion. GAAP fourth-quarter and full-year net income of $19 million and $822 million, or $0.03 and $1.21 per diluted share, respectively. Excluding net special items1, fourth-quarter and full-year net income of $192 million and $1.9 billion, or $0.29 and $2.65 per diluted share, respectively. Achieved best-ever fourth-quarter and full-year completion factor. Generated GAAP operating cash flow of $3.8 billion and the airline’s highest full-year free cash flow2 of $1.8 billion. Reduced total debt3 by $3.2 billion in 2023. The company is more than 75% of the way to its 2025 total debt reduction goal.“The American...

PORT ANGELES, Wash., Jan. 25, 2024 (GLOBE NEWSWIRE) — Matthew P. Deines, President and CEO, comments on financial results:“2023 was the most challenging year for many banks since the great recession,” said Matthew P. Deines, President and CEO. “That was certainly the case for First Northwest Bancorp and First Fed Bank. In spite of our challenges, we celebrated our 100th anniversary in 2023, and we continue to celebrate our customers, employees and communities as we enter our second century. While we posted an operating loss in the 4th quarter, largely due to a restructure of our bond portfolio, changes to market rates led to an increase in tangible book value per share compared to September 2023 and December 2022. We look forward to a challenging and prosperous 2024 as we remain focused on our customers and their...

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the pricing of an underwritten public offering of 4,615,384 shares of its common stock, at a public offering price of $32.50 per share. The gross proceeds to Tourmaline from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $150.0 million. All of the common stock is being offered by Tourmaline. In addition, Tourmaline has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of common stock at the public offering price, less the underwriting discounts...

SUNNYVALE, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), a knowledge automation platform for customer engagement, will announce its fiscal 2024 second quarter financial results after the close of regular market trading on Thursday, February 8, 2024, followed by an investor conference call and webcast at 2:00 p.m. Pacific Time (5:00 p.m. ET). Chief Executive Officer Ashu Roy and Chief Financial Officer Eric Smit will host the call and webcast.When: Thursday, February 8th at 2:00 p.m. Pacific Time (5:00 p.m. ET).Webcast: A live and archived webcast of the conference call can be accessed from the investors section of eGain’s website at www.egain.com.Dial In: To access the live call, dial 844-481-2704 (U.S. toll free) or +1 412-317-0660 (International) and ask to join the eGain earnings call.Replay: A phone...

Figure 1Atacicept 72-week Data From the Phase 2b ORIGIN Trial Are Consistent With a Profile of True Disease Modification– Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment – Placebo cohort participants who crossed over to atacicept 150 mg in the OLE had similar outcomes at 72 weeks as atacicept cohort in the first 36 weeks of the trial – Atacicept was generally well-tolerated in the OLE period of the trial, consistent with the randomized period – 72-week data provide additional confidence in the ongoing pivotal Phase 3 ORIGIN 3 clinical trial BRISBANE, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing...

Coherent infrared polarizersCoherent introduced a new family of infrared WGPs operating in the MWIR over 3-5 µm and the LWIR over 7-14 µm, based on meta optics wire technology that achieves a contrast ratio of an order of magnitude greater than the highest-performing comparable products in the industry.PITTSBURGH, Jan. 25, 2024 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a leader in diffractive optics, today announced the introduction of a family of mid-wavelength infrared (MWIR) and long-wavelength infrared (LWIR) wire-grid polarizers (WGPs) with industry-breakthrough performance for laser-based atmospheric remote sensing applications.Laser-based metrology such as for greenhouse gas monitoring is driving the demand for high-performance optics to improve measurement sensitivity. Coherent introduced a new family...